デフォルト表紙
市場調査レポート
商品コード
1392259

ゲノム編集の世界市場調査レポート:産業分析、規模、シェア、成長、動向、予測、2023年~2030年

Global Genome Editing Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日: | 発行: Value Market Research | ページ情報: 英文 331 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.16円
ゲノム編集の世界市場調査レポート:産業分析、規模、シェア、成長、動向、予測、2023年~2030年
出版日: 2023年11月01日
発行: Value Market Research
ページ情報: 英文 331 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ゲノム編集市場の世界需要は、調査期間2023年~2030年のCAGR18.23%で、2022年の75億9,000万米ドルから2030年にはほぼ289億8,000万米ドルの市場規模に達すると推定されます。

ゲノム編集は、生物のゲノム内のDNA配列を修正または変更するために使用される精密で的を絞った技術です。遺伝物質に意図的な変更を加えることで、科学者は生物のゲノム内の特定のDNA配列を追加、削除、変更することができます。

市場力学:

CRISPRやその他の編集技術の進歩は、遺伝子操作のより正確で利用しやすい方法を提供し、市場の拡大を促進します。ゲノム編集は生物医学研究において極めて重要な役割を担っており、疾病メカニズムの解明、創薬、潜在的治療法の発見に役立っています。遺伝性疾患の有病率の増加は、遺伝子変異を標的とする治療法の開拓を促進し、市場をさらに推進します。農業と家畜では、この編集は形質の強化、収量の向上、耐病性品種の開発に使用され、農業バイオテクノロジー分野での成長に寄与しています。支持的な規制の枠組み、研究開発投資の増加、さまざまな疾患の治療におけるゲノム編集の治療可能性が市場拡大を後押ししています。研究機関や業界関係者のコラボレーションが技術革新を促進し、新規の応用や治療につながります。オフターゲット効果や倫理的懸念などの課題にもかかわらず、ゲノム編集市場は、技術の進歩や、多様な分野にわたる生物医学研究、農業、治療介入に革命をもたらす可能性によって、拡大を続けています。

この調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析を対象としています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、ゲノム編集の世界市場における各セグメントを包括的に評価することもできます。ゲノム編集産業の成長と動向は、この調査に全体的なアプローチを提供します。

地域分析:

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおけるゲノム編集市場の現在および将来の需要を強調する地域展望をカバーしています。さらに、このレポートでは、すべての主要地域における個々のアプリケーションセグメントの需要、推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 ゲノム編集 - 産業分析

  • イントロダクション:市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 ゲノム編集の世界市場分析:技術別

  • 技術別概要
  • 実績データと予測データ
  • 技術別分析
  • メガヌクレアーゼ
  • (CRISPR)/Cas9
  • TALENs/メガタール
  • ZFN
  • その他

第6章 世界のゲノム編集市場分析:送達方法別

  • 送達方法別概要
  • 実績データと予測データ
  • 送達方法別分析
  • Ex-vivo
  • In-vivo

第7章 世界のゲノム編集市場分析:モード別

  • モード別概要
  • 実績データと予測データ
  • モード別分析
  • 委託
  • インハウス

第8章 ゲノム編集の世界市場分析:最終用途別

  • 最終用途別概要
  • 実績データと予測データ
  • 最終用途別分析
  • バイオテクノロジー・製薬企業
  • 学術・政府研究機関
  • 受託研究機関

第9章 ゲノム編集の世界市場分析:用途別

  • 概要:用途別
  • 実績データと予測データ
  • 分析:用途別
  • 遺伝子工学(細胞株工学、動物遺伝子工学、植物遺伝子工学、その他)
  • 臨床応用(診断、治療開発)

第10章 世界のゲノム編集市場分析:地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米:セグメント別
    • 北米:国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州:セグメント別
    • 欧州:国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋:セグメント別
    • アジア太平洋:国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ:セグメント別
    • ラテンアメリカ:国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ:セグメント別
    • 中東・アフリカ:国別売上分析
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東・アフリカ

第11章 ゲノム編集企業の競合情勢

  • ゲノム編集市場の競合
  • パートナーシップ/共同研究/合意
  • 合併・買収
  • 新製品の上市
  • その他の開発

第12章 企業プロファイル

  • 企業シェア分析
  • 市場集中度
  • Merck KGaA
  • Cibus
  • Recombinetics Inc.
  • Sangamo
  • Editas Medicine
  • Precision Biosciences
  • CRISPR Therapeutics
  • Intellia Therapeutics Inc.
  • Caribou Biosciences Inc.
  • Cellectis
  • AstraZeneca
  • Takara Bio USA
  • Horizon Discovery Group plc
  • Integrated DNA Technologies Inc.
  • Egenesis Inc.
  • GenScript
  • New England Biolabs
  • OriGene Technologies Inc.
  • Lonza
  • Thermo Fisher Scientific Inc.
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis by Technology (USD MN)
  • Meganucleases Market Sales by Geography (USD MN)
  • (CRISPR)/Cas9 Market Sales by Geography (USD MN)
  • TALENs/MegaTALs Market Sales by Geography (USD MN)
  • ZFN Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis Market by Delivery Method (USD MN)
  • Ex-vivo Market Sales by Geography (USD MN)
  • In-vivo Market Sales by Geography (USD MN)
  • Analysis by Mode (USD MN)
  • Contract Market Sales by Geography (USD MN)
  • In-house Market Sales by Geography (USD MN)
  • Analysis by End-use (USD MN)
  • Biotechnology & Pharmaceutical Companies Market Sales by Geography (USD MN)
  • Academic & Government Research Institutes Market Sales by Geography (USD MN)
  • Contract Research Organizations Market Sales by Geography (USD MN)
  • Analysis by Application (USD MN)
  • Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others) Market Sales by Geography (USD MN)
  • Clinical Applications (Diagnostics, Therapy Development) Market Sales by Geography (USD MN)
  • Global Genome Editing Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Genome Editing Report
  • Market Research Process
  • Market Research Methodology
  • Global Genome Editing Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Technology
  • Market Attractiveness Analysis by Delivery Method
  • Market Attractiveness Analysis by Mode
  • Market Attractiveness Analysis by End-use
  • Market Attractiveness Analysis by Application
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Technology (USD MN)
  • Meganucleases Market Sales by Geography (USD MN)
  • (CRISPR)/Cas9 Market Sales by Geography (USD MN)
  • TALENs/MegaTALs Market Sales by Geography (USD MN)
  • ZFN Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Delivery Method (USD MN)
  • Ex-vivo Market Sales by Geography (USD MN)
  • In-vivo Market Sales by Geography (USD MN)
  • Global Market Analysis by Mode (USD MN)
  • Contract Market Sales by Geography (USD MN)
  • In-house Market Sales by Geography (USD MN)
  • Global Market Analysis by End-use (USD MN)
  • Biotechnology & Pharmaceutical Companies Market Sales by Geography (USD MN)
  • Academic & Government Research Institutes Market Sales by Geography (USD MN)
  • Contract Research Organizations Market Sales by Geography (USD MN)
  • Global Market Analysis by Application (USD MN)
  • Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others) Market Sales by Geography (USD MN)
  • Clinical Applications (Diagnostics, Therapy Development) Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112112859

The global demand for Genome Editing Market is presumed to reach the market size of nearly USD 28.98 BN by 2030 from USD 7.59 BN in 2022 with a CAGR of 18.23% under the study period 2023 - 2030.

Genome editing is a precise and targeted technique used to modify or alter the DNA sequence within an organism's genome. It involves making intentional changes to the genetic material, enabling scientists to add, remove, or modify specific DNA sequences within an organism's genome.

MARKET DYNAMICS:

Advancements in CRISPR and other editing technologies offer more precise and accessible methods for genetic manipulation, fostering market expansion. Genome editing plays a pivotal role in biomedical research, aiding in understanding disease mechanisms, drug discovery, and potential therapies, driving its demand in the biopharmaceutical sector. The increasing prevalence of genetic disorders fuels the development of therapies targeting genetic mutations, further propelling the market. In agriculture and livestock, this editing is used to enhance traits, improve yields, and develop disease-resistant varieties, contributing to its growth in agricultural biotechnology. Supportive regulatory frameworks, increased R&D investments, and the therapeutic potential of genome editing in treating various conditions fuel market expansion. Collaborations among institutions and industry players drive innovation, leading to novel applications and therapies. Despite challenges like off-target effects and ethical concerns, the genome editing market continues to expand, driven by technological advancements and its potential to revolutionize biomedical research, agriculture, and therapeutic interventions across diverse sectors.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of genome editing. The growth and trends of genome editing industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the genome editing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Technology

  • Meganucleases
  • CRISPR)/Cas9
  • TALENs/MegaTALs
  • ZFN
  • Others

By Delivery Method

  • Ex-Vivo
  • In-Vivo

By Mode

  • Contract
  • In-House

By End-Use

  • Biotechnology & Pharmaceutical Companies
  • Academic & Government Research Institutes
  • Contract Research Organizations

By Application

  • Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others)
  • Clinical Applications (Diagnostics, Therapy Development)

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Genome Editing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Genome Editing market include Merck KGaA, Cibus, Recombinetics, Inc., Sangamo, Editas Medicine, Precision Biosciences, CRISPR Therapeutics, Intellia Therapeutics, Inc., Caribou Biosciences, Inc., Cellectis, AstraZeneca, Takara Bio USA, Horizon Discovery Group plc, Integrated DNA Technologies, Inc., Egenesis Inc., GenScript, New England Biolabs, OriGene Technologies, Inc., Lonza, Thermo Fisher Scientific, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . GENOME EDITING - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Technology
    • 3.7.2 Market Attractiveness Analysis By Delivery Method
    • 3.7.3 Market Attractiveness Analysis By Mode
    • 3.7.4 Market Attractiveness Analysis By End-use
    • 3.7.5 Market Attractiveness Analysis By Application
    • 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL GENOME EDITING MARKET ANALYSIS BY TECHNOLOGY

  • 5.1 Overview by Technology
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Technology
  • 5.4 Meganucleases Historic and Forecast Sales by Regions
  • 5.5 (CRISPR)/Cas9 Historic and Forecast Sales by Regions
  • 5.6 TALENs/MegaTALs Historic and Forecast Sales by Regions
  • 5.7 ZFN Historic and Forecast Sales by Regions
  • 5.8 Others Historic and Forecast Sales by Regions

6 . GLOBAL GENOME EDITING MARKET ANALYSIS BY DELIVERY METHOD

  • 6.1 Overview by Delivery Method
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Delivery Method
  • 6.4 Ex-vivo Historic and Forecast Sales by Regions
  • 6.5 In-vivo Historic and Forecast Sales by Regions

7 . GLOBAL GENOME EDITING MARKET ANALYSIS BY MODE

  • 7.1 Overview by Mode
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Mode
  • 7.4 Contract Historic and Forecast Sales by Regions
  • 7.5 In-house Historic and Forecast Sales by Regions

8 . GLOBAL GENOME EDITING MARKET ANALYSIS BY END-USE

  • 8.1 Overview by End-use
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by End-use
  • 8.4 Biotechnology & Pharmaceutical Companies Historic and Forecast Sales by Regions
  • 8.5 Academic & Government Research Institutes Historic and Forecast Sales by Regions
  • 8.6 Contract Research Organizations Historic and Forecast Sales by Regions

9 . GLOBAL GENOME EDITING MARKET ANALYSIS BY APPLICATION

  • 9.1 Overview by Application
  • 9.2 Historical and Forecast Data
  • 9.3 Analysis by Application
  • 9.4 Genetic Engineering (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others) Historic and Forecast Sales by Regions
  • 9.5 Clinical Applications (Diagnostics, Therapy Development) Historic and Forecast Sales by Regions

10 . GLOBAL GENOME EDITING MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.3.2. North America By Segment Sales Analysis
    • 10.3.3. North America By Country Sales Analysis
    • 10.3.4. United State Sales Analysis
    • 10.3.5. Canada Sales Analysis
    • 10.3.6. Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.4.2. Europe by Segment Sales Analysis
    • 10.4.3. Europe by Country Sales Analysis
    • 10.4.4. United Kingdom Sales Analysis
    • 10.4.5. France Sales Analysis
    • 10.4.6. Germany Sales Analysis
    • 10.4.7. Italy Sales Analysis
    • 10.4.8. Russia Sales Analysis
    • 10.4.9. Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.5.2. Asia Pacific by Segment Sales Analysis
    • 10.5.3. Asia Pacific by Country Sales Analysis
    • 10.5.4. China Sales Analysis
    • 10.5.5. India Sales Analysis
    • 10.5.6. Japan Sales Analysis
    • 10.5.7. South Korea Sales Analysis
    • 10.5.8. Australia Sales Analysis
    • 10.5.9. South East Asia Sales Analysis
    • 10.5.10. Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.6.2. Latin America by Segment Sales Analysis
    • 10.6.3. Latin America by Country Sales Analysis
    • 10.6.4. Brazil Sales Analysis
    • 10.6.5. Argentina Sales Analysis
    • 10.6.6. Peru Sales Analysis
    • 10.6.7. Chile Sales Analysis
    • 10.6.8. Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.7.2. Middle East & Africa by Segment Sales Analysis
    • 10.7.3. Middle East & Africa by Country Sales Analysis
    • 10.7.4. Saudi Arabia Sales Analysis
    • 10.7.5. UAE Sales Analysis
    • 10.7.6. Israel Sales Analysis
    • 10.7.7. South Africa Sales Analysis
    • 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE GENOME EDITING COMPANIES

  • 11.1. Genome Editing Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12 . COMPANY PROFILES OF GENOME EDITING INDUSTRY

  • 12.1. Company Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. Merck KGaA
    • 12.3.1. Company Overview
    • 12.3.2. Company Revenue
    • 12.3.3. Products
    • 12.3.4. Recent Developments
  • 12.4. Cibus
    • 12.4.1. Company Overview
    • 12.4.2. Company Revenue
    • 12.4.3. Products
    • 12.4.4. Recent Developments
  • 12.5. Recombinetics Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Company Revenue
    • 12.5.3. Products
    • 12.5.4. Recent Developments
  • 12.6. Sangamo
    • 12.6.1. Company Overview
    • 12.6.2. Company Revenue
    • 12.6.3. Products
    • 12.6.4. Recent Developments
  • 12.7. Editas Medicine
    • 12.7.1. Company Overview
    • 12.7.2. Company Revenue
    • 12.7.3. Products
    • 12.7.4. Recent Developments
  • 12.8. Precision Biosciences
    • 12.8.1. Company Overview
    • 12.8.2. Company Revenue
    • 12.8.3. Products
    • 12.8.4. Recent Developments
  • 12.9. CRISPR Therapeutics
    • 12.9.1. Company Overview
    • 12.9.2. Company Revenue
    • 12.9.3. Products
    • 12.9.4. Recent Developments
  • 12.10. Intellia Therapeutics Inc.
    • 12.10.1. Company Overview
    • 12.10.2. Company Revenue
    • 12.10.3. Products
    • 12.10.4. Recent Developments
  • 12.11. Caribou Biosciences Inc.
    • 12.11.1. Company Overview
    • 12.11.2. Company Revenue
    • 12.11.3. Products
    • 12.11.4. Recent Developments
  • 12.12. Cellectis
    • 12.12.1. Company Overview
    • 12.12.2. Company Revenue
    • 12.12.3. Products
    • 12.12.4. Recent Developments
  • 12.13. AstraZeneca
    • 12.13.1. Company Overview
    • 12.13.2. Company Revenue
    • 12.13.3. Products
    • 12.13.4. Recent Developments
  • 12.14. Takara Bio USA
    • 12.14.1. Company Overview
    • 12.14.2. Company Revenue
    • 12.14.3. Products
    • 12.14.4. Recent Developments
  • 12.15. Horizon Discovery Group plc
    • 12.15.1. Company Overview
    • 12.15.2. Company Revenue
    • 12.15.3. Products
    • 12.15.4. Recent Developments
  • 12.16. Integrated DNA Technologies Inc.
    • 12.16.1. Company Overview
    • 12.16.2. Company Revenue
    • 12.16.3. Products
    • 12.16.4. Recent Developments
  • 12.17. Egenesis Inc.
    • 12.17.1. Company Overview
    • 12.17.2. Company Revenue
    • 12.17.3. Products
    • 12.17.4. Recent Developments
  • 12.18. GenScript
    • 12.18.1. Company Overview
    • 12.18.2. Company Revenue
    • 12.18.3. Products
    • 12.18.4. Recent Developments
  • 12.19. New England Biolabs
    • 12.19.1. Company Overview
    • 12.19.2. Company Revenue
    • 12.19.3. Products
    • 12.19.4. Recent Developments
  • 12.20. OriGene Technologies Inc.
    • 12.20.1. Company Overview
    • 12.20.2. Company Revenue
    • 12.20.3. Products
    • 12.20.4. Recent Developments
  • 12.21. Lonza
    • 12.21.1. Company Overview
    • 12.21.2. Company Revenue
    • 12.21.3. Products
    • 12.21.4. Recent Developments
  • 12.22. Thermo Fisher Scientific Inc.
    • 12.22.1. Company Overview
    • 12.22.2. Company Revenue
    • 12.22.3. Products
    • 12.22.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies